Attached files
| file | filename |
|---|---|
| EX-10.18 - NON-EMPLOYEE DIRECTOR COMPENSATION POLICY - Iterum Therapeutics plc | d522368dex1018.htm |
| EX-10.6 - 2018 EQUITY INCENTIVE PLAN - Iterum Therapeutics plc | d522368dex106.htm |
| EX-5.1 - OPINION OF A&L GOODBODY - Iterum Therapeutics plc | d522368dex51.htm |
| EX-3.2 - FORM OF CONSTITUTION - Iterum Therapeutics plc | d522368dex32.htm |
| EX-3.1 - CONSTITUTION, AS CURRENTLY IN EFFECT. - Iterum Therapeutics plc | d522368dex31.htm |
| S-1/A - AMENDMENT #2 TO FORM S-1 - Iterum Therapeutics plc | d522368ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Iterum Therapeutics plc (formerly Iterum Therapeutics Limited):
We consent to the use of our report dated March 9, 2018, except as for the effects of the Reverse Share Split discussed in Note 12 to the consolidated financial statements, as to which the date is May 16, 2018 with respect to the consolidated balance sheets of Iterum Therapeutics plc (formerly Iterum Therapeutics Limited) as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, changes in convertible preferred shares and shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2017, and the related notes (collectively, the consolidated financial statements), included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG
Dublin, Ireland
May 16, 2018